Triple perspective: assessing deep brain stimulation outcomes in Parkinson's disease.
Triple perspective: assessing deep brain stimulation outcomes in Parkinson's disease.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Milan, IT · Author affiliation
Department of Oncology and Hemato-Oncology, University of Milan, Via Santa Sofia 9/1, Milan, 20122, Italy.Location evidence
Follow the study behind this paper
Following thinking and behaviour after brain stimulation
The registry links this paper to the study.
A plain-language reading has not been prepared for this paper yet.
Original abstract
BACKGROUND: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for advanced Parkinson’s disease (PD), often leading to positive motor and non-motor outcomes. While objective motor improvements after DBS are well documented, less is known about how patients and all those involved in their care perceive these benefits on a subjective level. OBJECTIVES: The primary aim of the study was to investigate the perception gap between patients, caregivers, and treating neurologists regarding DBS physical and psychological benefits in PD and their correlates. METHODS: 25 PD patients (age 58.9 ± 8.0 years; 9 women) who underwent bilateral STN-DBS, along with their caregivers and neurologists, rated perceived psychological and physical improvements 6 months after surgery using a two-item Visual Analogue Scales (VAS, 0–10). Intraclass correlation coefficients (ICC [95% confidence interval]) were calculated to assess reliability between raters. RESULTS: Patients, caregivers, and neurologists reported an average improvement of about 60% in the psychological domain and over 75% in the physical domain (p < 0.001). No significant differences emerged between groups in two domains (p > 0.05). Inter-rater agreement was moderate-to-good for psychological improvement (0.74 [0.41–0.90], p < 0.001), moderate for physical improvement (0.69 [0.27–0.88], p = 0.003), and good overall (0.79 [0.50–0.92], p < 0.001). CONCLUSIONS: PD patients, caregivers, and neurologists largely agree on the benefits of DBS six months post-surgery, reinforcing the reliability of patient self-report in outcome assessment. Integrating patient self-reports with proxy assessments enhances the evaluation of DBS outcomes, supporting a more comprehensive and patient-centered approach to both treatment assessment and post-surgical care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06329726. Registered on 26 March 2024.